The Insider and EVP – CL&AO of Vertex Pharmaceuticals (VRTX), Michael Parini, Sold 85 Shares; Unilever N.V. (UN) Covered By 7 Bulls

Unilever N.V. (NYSE:UN) Logo

Unilever N.V. (NYSE:UN) Ratings Coverage

Among 11 analysts covering Unilever NV (NYSE:UN), 7 have Buy rating, 1 Sell and 3 Hold. Therefore 64% are positive. Unilever NV had 13 analyst reports since September 25, 2015 according to SRatingsIntel. Credit Suisse upgraded Unilever N.V. (NYSE:UN) on Tuesday, December 8 to “Neutral” rating. The firm has “Buy” rating given on Tuesday, December 13 by Jefferies. The stock of Unilever N.V. (NYSE:UN) earned “Buy” rating by Berenberg on Friday, September 25. UBS upgraded the stock to “Buy” rating in Wednesday, March 28 report. The rating was upgraded by Argus Research on Friday, March 23 to “Buy”. On Friday, March 24 the stock rating was upgraded by Barclays Capital to “Overweight”. The stock of Unilever N.V. (NYSE:UN) earned “Outperform” rating by Bernstein on Monday, August 22. On Wednesday, December 7 the stock rating was downgraded by JP Morgan to “Neutral”. On Thursday, August 10 the stock rating was downgraded by RBC Capital Markets to “Underperform”. The firm has “Buy” rating by Citigroup given on Wednesday, August 31. See Unilever N.V. (NYSE:UN) latest ratings:

28/03/2018 Broker: UBS Rating: Buy Upgrade
23/03/2018 Broker: Argus Research Old Rating: Hold New Rating: Buy Upgrade

The stock increased 0.40% or $0.62 during the last trading session, reaching $156.16. About 971,857 shares traded. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 76.59% since May 17, 2017 and is uptrending. It has outperformed by 65.04% the S&P500.

Michael Parini who serves as EVP – CL&AO of Vertex Pharmaceuticals Inc Ma a few days ago sold 85 shares of the corporation. The significant insider trade has $13,241 US Dollars total value, at an average price-per-share of $155.8. This is not his first insider trade, in the last month, he unloaded another 43,094 shares worth $6,841,738 USD. The posibility that the transaction stays unnoticed is little considering the large amount of cash involved. Now, Michael Parini owns 39,609 shares which are roughly 0.02% of Vertex Pharmaceuticals Inc Ma’s market cap (share price times the number of shares outstanding).

Among 30 analysts covering Vertex Pharmaceuticals (NASDAQ:VRTX), 26 have Buy rating, 0 Sell and 4 Hold. Therefore 87% are positive. Vertex Pharmaceuticals has $212.0 highest and $85.0 lowest target. $180.63’s average target is 15.67% above currents $156.16 stock price. Vertex Pharmaceuticals had 102 analyst reports since July 31, 2015 according to SRatingsIntel. The rating was maintained by Credit Suisse with “Outperform” on Tuesday, February 13. Oppenheimer maintained the stock with “Buy” rating in Friday, April 27 report. Cowen & Co maintained it with “Buy” rating and $20000 target in Tuesday, August 1 report. The company was maintained on Friday, September 29 by Stifel Nicolaus. William Blair downgraded the stock to “Market Perform” rating in Tuesday, November 1 report. The stock of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) earned “Buy” rating by Needham on Friday, June 23. Jefferies maintained Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) rating on Wednesday, July 19. Jefferies has “Buy” rating and $18500 target. The firm has “Buy” rating given on Wednesday, July 19 by Maxim Group. The firm has “Outperform” rating by RBC Capital Markets given on Thursday, April 28. On Wednesday, July 19 the stock rating was upgraded by Raymond James to “Outperform”.

Vertex Pharmaceuticals Incorporated discovers, develops, makes, and commercializes medicines for serious diseases. The company has market cap of $39.79 billion. The firm focuses on developing and commercializing therapies for the treatment of cystic fibrosis and advancing its research and development programs. It has a 150.3 P/E ratio. It markets ORKAMBI (lumacaftor in combination with ivacaftor) for the treatment of patients with CF 12 years of age and older who have two copies (homozygous) of the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; and KALYDECO (ivacaftor) for the treatment of patients with CF 2 years of age and older who have the G551D mutation or other specified mutations in their CFTR gene.

Since December 11, 2017, it had 0 buys, and 45 selling transactions for $106.34 million activity. Parini Michael had sold 2,125 shares worth $333,965 on Friday, January 12. $342,142 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) was sold by Silva Paul M. 6,459 Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) shares with value of $1.09 million were sold by Arbuckle Stuart A. The insider Sachdev Amit sold 46,172 shares worth $7.33M. ALTSHULER DAVID sold 1,796 shares worth $287,360. MCGLYNN MARGARET G sold $1.70M worth of stock or 10,000 shares. SMITH IAN F sold $334,232 worth of stock.

Analysts await Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to report earnings on July, 25. They expect $0.42 earnings per share, up 320.00% or $0.32 from last year’s $0.1 per share. VRTX’s profit will be $107.03M for 92.95 P/E if the $0.42 EPS becomes a reality. After $0.54 actual earnings per share reported by Vertex Pharmaceuticals Incorporated for the previous quarter, Wall Street now forecasts -22.22% negative EPS growth.

Investors sentiment decreased to 1.34 in Q4 2017. Its down 0.28, from 1.62 in 2017Q3. It turned negative, as 53 investors sold Vertex Pharmaceuticals Incorporated shares while 160 reduced holdings. 72 funds opened positions while 213 raised stakes. 232.48 million shares or 0.46% more from 231.42 million shares in 2017Q3 were reported. Earnest Ptnrs Ltd has 0% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) for 111 shares. Valley National Advisers holds 151 shares or 0.01% of its portfolio. Whittier Of Nevada reported 0% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Lazard Asset Lc holds 0.05% or 173,986 shares in its portfolio. Cornerstone Advsr Inc holds 14,000 shares. State Of Tennessee Treasury Department holds 0.12% or 186,325 shares in its portfolio. Columbus Circle holds 1.06% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) or 372,663 shares. Contravisory Mgmt accumulated 30 shares. Goldman Sachs Group Inc Inc holds 3.23M shares. Everence Cap Mngmt Incorporated has 0.19% invested in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). State Treasurer State Of Michigan stated it has 0.09% of its portfolio in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Credit Suisse Ag holds 494,038 shares. Gotham Asset Mgmt stated it has 0.03% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). Thompson Siegel And Walmsley Limited Liability reported 0% stake. Ameriprise Financial has invested 0.36% in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

More recent Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) news were published by: Streetinsider.com which released: “Vertex Pharma (VRTX), Alexion Pharma (ALXN) Least Impacted from Trump Drug Policies – RBC” on May 15, 2018. Also Seekingalpha.com published the news titled: “Vertex Pharmaceuticals Heads Toward An Important Tipping Point” on May 01, 2018. Fool.com‘s news article titled: “Vertex Pharmaceuticals Takes a Detour Around the FDA’s Roadblock” with publication date: April 30, 2018 was also an interesting one.

The stock decreased 0.57% or $0.32 during the last trading session, reaching $55.83. About 1.02M shares traded. Unilever N.V. (NYSE:UN) has risen 6.36% since May 17, 2017 and is uptrending. It has underperformed by 5.19% the S&P500.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Institutional Positions Chart